Tenet Healthcare (NYSE: THC) had its target price upped by Credit Suisse from $31.00 to $44.00 in a report issued on Wednesday.

A number of other firms have also recently commented on THC. Analysts at Mizuho raised their price target on shares of Tenet Healthcare from $40.00 to $41.00 in a research note to investors on Wednesday. They now have a buy rating on the stock. Separately, analysts at Barclays Capital raised their price target on shares of Tenet Healthcare from $36.00 to $41.00 in a research note to investors on Wednesday. They now have an equal weight rating on the stock. Finally, analysts at BMO Capital Markets reiterated a market perform rating on shares of Tenet Healthcare in a research note to investors on Wednesday. They now have a $40.00 price target on the stock, up previously from $38.00.

Tenet Healthcare traded up 0.31% on Wednesday, hitting $39.43. Tenet Healthcare has a 52-week low of $17.24 and a 52-week high of $40.94. The stock’s 50-day moving average is currently $38.27. The company has a market cap of $4.178 billion and a price-to-earnings ratio of 39.23.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.